CHECKPOINT THERAPEUTICS INC
BiotechCHECKPOINT THERAPEUTICS INC is a biotechnology company focused on Immunology, Oncology, Dermatology.
CHECKPOINT THERAPEUTICS INC's Key Drugs
CHECKPOINT THERAPEUTICS INC's core commercial portfolio centers on UNLOXCYT, spanning Immunology and Oncology — its most strategically important drugs approved in the last 15 years.
CHECKPOINT THERAPEUTICS INC's Recent FDA Approvals
CHECKPOINT THERAPEUTICS INC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
CHECKPOINT THERAPEUTICS INC's Therapeutic Areas
CHECKPOINT THERAPEUTICS INC's approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CHECKPOINT THERAPEUTICS INC's Top Competitors
CHECKPOINT THERAPEUTICS INC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and PF PRISM CV. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CHECKPOINT THERAPEUTICS INC Pipeline Snapshot
CHECKPOINT THERAPEUTICS INC has 18 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 8 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • UNLOXCYT leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2024-12-13
- Latest
- 2025-11-21
- Applications
- 1